Milestones in Medicine: History & Evolving Role of Interferon in Myeloproliferative Neoplasms

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon and emerging novel agents in the treatment of patients with myeloproliferative neoplasms.

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses the RUXOPeg trial in myelofibrosis.

Suman A. Kambhampati, MD, discusses emerging data in myeloproliferative neoplasms and what is coming on the horizon.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the use of ropeginterferon alfa-2b in myeloproliferative neoplasms (MPNs).

Jean-Jacques Kiladjian, MD, PhD, professor of clinical pharmacology, Paris Diderot University, consultant hematologist, head, Clinical Investigation Center, Saint Louis Hospital, Paris, France, discusses a study of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasms.

Suman Kambhampati, MD, co-director of the Blood Cancer Center at Sarah Cannon Research Institute, HCA Midwest Health, discusses the role of interferon in the treatment of patients with myeloproliferative neoplasms.

Abdulraheem Yacoub, MD, discusses the development of interferon and its current role in the management of patients with myeloproliferative neoplasms.

Richard T. Silver, MD, discusses the history of interferon and shares insight on why the drug still holds its place in the treatment of patients with MPNs.

Srdan Verstovsek, MD, PhD, discusses the use of interferon in rare blood diseases.

Ruben A. Mesa, MD, discusses the evolving role of interferon in the treatment of patients with MPNs, highlights recent treatment advances, and shares insight on the future of treatment for these patients.